Natera is trading 6.03% lower at $367.44, with no verified company-specific catalyst identified. - Third-quarter results are scheduled for after the market closes and have not yet been reported. - The Nasdaq Composite is down 2.25%, while the provided biotech sector context shows a 2.05% rise. The weak broader market may be contributing, but the mixed sector picture leaves the precise driver uncertain.